Valuation: Verastem, Inc.

Market Cap 39Cr 34Cr 32Cr 29Cr 56Cr 3.72TCr 57Cr 379Cr 147.39Cr 1.84TCr 147.14Cr 143.95Cr 6.35TCr P/E 2026 *
-2.82x
P/E 2027 * -3.99x
Enterprise Value 23Cr 20Cr 18Cr 17Cr 32Cr 2.15TCr 33Cr 219.44Cr 85Cr 1.06TCr 85Cr 83Cr 3.67TCr EV / Sales 2026 *
2.22x
EV / Sales 2027 * 1.02x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+9.08%
1 week+27.36%
Current month+27.36%
1 month+32.56%
3 months-10.73%
6 months-36.32%
Current year-36.98%
1 week 3.84
Extreme 3.835
4.98
1 month 3.43
Extreme 3.43
4.98
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
45.78
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/06Sell

Chief Executive Officer

-20,871 0.0339%
22/06Sell

Chief Financial Officer

-4,089 0.0066%
21/05Free

Chairman

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+8.74%+27.36%+3.73%-39.19% 39Cr
-0.10%+0.10%+74.33%+133.26% 5.77TCr
-3.80%-6.24%+67.04%+86.36% 5.47TCr
+0.38%+1.33%-14.32%-11.76% 2.38TCr
+1.17%+5.80%+16.35%+468.00% 2.42TCr
-2.70%+4.25%+40.38%-3.72% 1.98TCr
+3.78%+5.65%+44.99%-26.23% 1.71TCr
+3.46%+17.72%+206.66%+364.07% 1.68TCr
-1.81%+18.00%+41.99% - 1.56TCr
+2.79%+4.84%+29.18%+195.42% 1.4TCr
Average +1.22%+6.68%+51.03%+129.58% 2.44TCr
Weighted average by Cap. -0.39%+3.36%+57.83%+138.96%

Financials

2026 *2027 *
Net sales 10Cr 8.95Cr 8.25Cr 7.65Cr 15Cr 970.83Cr 15Cr 99Cr 38Cr 479.13Cr 38Cr 38Cr 1.66TCr 18Cr 16Cr 14Cr 13Cr 25Cr 1.7TCr 26Cr 172.89Cr 67Cr 837.41Cr 67Cr 66Cr 2.89TCr
Net income -17Cr -15Cr -13Cr -12Cr -24Cr -1.58TCr -24Cr -160.73Cr -63Cr -778.49Cr -62Cr -61Cr -2.69TCr -14Cr -12Cr -11Cr -11Cr -20Cr -1.34TCr -20Cr -136.92Cr -53Cr -663.16Cr -53Cr -52Cr -2.29TCr
Net Debt -16Cr -14Cr -13Cr -12Cr -23Cr -1.57TCr -24Cr -159.56Cr -62Cr -772.85Cr -62Cr -61Cr -2.67TCr -21Cr -18Cr -17Cr -16Cr -30Cr -1.99TCr -30Cr -202.69Cr -79Cr -981.76Cr -79Cr -77Cr -3.39TCr
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
08/26/08 $4.850 +8.74% 28,42,502
06/26/06 $4.460 -0.89% 18,11,512
02/26/02 $4.500 +9.76% 29,67,738
01/26/01 $4.100 +7.33% 21,86,504
30/26/30 $3.820 0.00% 34,45,491
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.460USD
Average target price
15.00USD
Spread / Average Target
+236.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock